The abstract is read at the publisher; the summary is JClub's.
In HER2-positive advanced biliary tract cancer, a first-line trastuzumab+nivolumab plus gemcitabine/cisplatin regimen achieved a 55% objective response rate among 40 participants.
- Why it matters: Outcomes in biliary tract cancers remain poor, and although checkpoint inhibitors entered first-line chemotherapy, HER2-targeted chemoimmunotherapy has not been prospectively tested.
- What they did: The multi-institutional open-label phase 1b/2 HERBOT study (KCSG-HB23-05) evaluated the HER2-targeted quadruplet as first-line therapy, with response assessed in 40 HER2-positive advanced BTC participants.
- The result: Disease control was 95% and median progression-free survival was 10.6 months with median overall survival not reached; higher HER2 3+ cell proportions were linked to greater clinical benefit.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.